PipelineReview.com - All Products

Show Cart

All Products

Results 41 - 60 of 194

Jul 2018 CXCR2, CCR2 & CCR4 Chemokine Receptor Antagonists – Target Pipeline List 07/2018

Jul 2018 Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

(Discount: 40.00%)

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Jul 2018 CXCR4 Chemokine Receptor Antagonists – Target Pipeline List 07/2018

Jul 2018 Aryl Hydrocarbon Receptor (AHR) Agonists & Antagonists – Target Pipeline List 07/2018

Jul 2018 Novel IDO & TDO Inhibitors – Target Pipeline List 07/2018

Jul 2018 CSF-1R ( Colony Stimulating Factor 1 Receptor) Antagonists – Target Pipeline List 07/2018

Jul 2018 TGF-beta Inhibitors – Target Pipeline List 07/2018

Jul 2018 Adenosine Pathway Modulation via A2AR, CD39 & CD73 – Target Pipeline List 07/2018

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Jul 2018 CTLA-4 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 LAG-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIM-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIGIT Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 B7-H3 Immune Checkpoint Inhibitors - Target Pipeline List 07/2018

Jul 2018 CD40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 GITR Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 OX40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 CD27 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 ICOS Immune Checkpoint Activators – Target Pipeline List 07/2018

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing